Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243994 | 0.86 | UTS2R (0.52) | UTS2RTRPA1KDM4EGAAPDPK1 | |
| SCHEMBL1662606 | 0.82 | UTS2R (0.56) | UTS2RTRPA1KDM4ECYP3A4ACHE | |
| SCHEMBL19505620 | 0.81 | TRPA1 (0.50) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL700943 | 0.81 | TRPA1 (0.50) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL5410969 | 0.81 | TRPA1 (0.46) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL1274224 | 0.80 | MAPK10 (0.61) | UTS2RACHEMAPK10MAPK8 | |
| SCHEMBL3104864 | 0.79 | KDM4E (0.48) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL11756891 | 0.79 | TRPA1 (0.54) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL31032755 | 0.79 | TRPA1 (0.54) | TRPA1KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL10831906 | 0.78 | GAA (0.51) | TRPA1GAAACHEADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| CN-100384417-C | Pyranoindazoles and use thereof for preparing medicament for treating glaucoma | ALCON INC (CH) | 2008-04-30 | — | — | CN | disclosed |
| CN-1592619-A | Pyranoindazoles and their use for the treatment of glaucoma | ALCON INC (CH) | 2005-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | UTS2R 3259/4885TRPA1 963/4885KDM4E 2622/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | UTS2R 2503/4885TRPA1 4748/4885KDM4E 1867/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | UTS2R 3353/4885TRPA1 856/4885KDM4E 2624/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | UTS2R 2503/4885TRPA1 4748/4885KDM4E 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.